To address this question, we have engineered T cells expressing UniCARs that use an affinity-enhanced monomeric streptavidin 2 (mSA2) biotin-binding domain (7) as an extracellular recognition unit that could target HER2+ tumor cells through biotinylated trastuzumab (BT). Here, ERBB2 is linked to neoplasm.